Paige Taggart's questions to Biostem Technologies Inc (BSEM) leadership • Q2 2024
Question
Paige Taggart of APT Consulting asked for more detail on how investors should view the clinical trial initiative in terms of its potential impact on revenue, market expansion, and product coverage.
Answer
Executive Jason Matuszewski explained that the clinical trials, like the DFU study for AW2, are crucial for generating the data needed to address potential Medicare LCD requirements. He anticipates the multisite RCT could be completed in a 12-to-18-month timeframe. Positive data is expected to support expanded payer coverage and commercial advancements. The company also plans to initiate trials for other wound types, such as VLU and pressure ulcers, later in the year.